TITLE:
Phase II Study of Fluconazole for Lymphocutaneous and Visceral Sporotrichosis

CONDITION:
Sporotrichosis

INTERVENTION:
fluconazole

SUMMARY:

      OBJECTIVE:

      I. Evaluate the efficacy of fluconazole in patients with lymphocutaneous or visceral
      sporotrichosis.
    

DETAILED DESCRIPTION:

      PROTOCOL OUTLINE:

      Patients are treated with daily oral fluconazole for up to 24 months. Follow-up continues
      for at least 1 year.
    

ELIGIBILITY:
Gender: All
Age: 12 Years to N/A
Criteria:

        PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics-- Presumptive evidence of sporotrichosis Culture-proven
        sporotrichosis determined on study Relapsing disease following antifungal therapy eligible
        if culture positive for Sporothrix schenckii prior to entry No life-threatening disease No
        central nervous system sporotrichosis --Prior/Concurrent Therapy-- No concurrent drugs
        known to react with fluconazole No more than 3 days of systemic antifungals for current
        sporotrichosis episode --Patient Characteristics-- Hepatic: Liver function tests no
        greater than 5 times normal Other: No HIV infection No pregnant or nursing women
      
